Norge - norsk - Statens legemiddelverk

aco hud nordic ab - jern(ii)sulfat, tørret - depottablett - 100 mg

Den europeiske union - norsk - EMA (European Medicines Agency)

roche registration gmbh - pirfenidone - idiopathic pulmonary fibrosis; lung diseases; respiratory tract diseases - immunsuppressive - esbriet is indicated in adults for the treatment of idiopathic pulmonary fibrosis.

Norge - norsk - Statens legemiddelverk

sandoz gmbh - rifampicin - kapsel, hard - 150 mg

Norge - norsk - Statens legemiddelverk

sandoz gmbh - rifampicin - kapsel, hard - 300 mg

Norge - norsk - Statens legemiddelverk

2care4 aps - rifampicin - kapsel, hard - 300 mg

Norge - norsk - Statens legemiddelverk

orifarm as - rifampicin - kapsel, hard - 300 mg

Den europeiske union - norsk - EMA (European Medicines Agency)

novartis europharm limited - dabrafenib mesilate - melanom - antineoplastiske midler - melanomadabrafenib as monotherapy or in combination with trametinib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a braf v600 mutation (see sections 4. 4 og 5. adjuvant behandling av melanomadabrafenib i kombinasjon med trametinib er indikert for adjuvant behandling av voksne pasienter med stadium iii melanom med en braf v600 mutasjon, følgende komplett reseksjon. non-small cell lung cancer (nsclc)dabrafenib in combination with trametinib is indicated for the treatment of adult patients with advanced non-small cell lung cancer with a braf v600 mutation.

Den europeiske union - norsk - EMA (European Medicines Agency)

pfizer europe ma eeig - tigecycline - bacterial infections; skin diseases, bacterial; soft tissue infections - antibakterielle midler for systemisk bruk, - tygacil is indicated in adults and in children from the age of eight years for the treatment of the following infections: , complicated skin and soft tissue infections (cssti), excluding diabetic foot infections, complicated intra-abdominal infections (ciai) , tygacil should be used only in situations where other alternative antibiotics are not suitable. det bør vurderes å offisielle retningslinjer for riktig bruk av antibakterielle midler. riktig bruk av antibakterielle midler.

Den europeiske union - norsk - EMA (European Medicines Agency)

amgen europe b.v. - panitumumab - colorektale neoplasmer - antineoplastiske midler - vectibix is indicated for the treatment of adult patients with wild-type ras metastatic colorectal cancer (mcrc): , in first-line in combination with folfox or folfiri. i andre linje i kombinasjon med folfiri for pasienter som har mottatt første-linje fluoropyrimidine-basert kjemoterapi (med unntak av irinotecan). som monoterapi etter svikt av fluoropyrimidine-, oxaliplatin-og irinotecan-inneholder kjemoterapi regimer.

Den europeiske union - norsk - EMA (European Medicines Agency)

astellas pharma europe b.v. - enzalutamide - prostata neoplasmer - endokrin terapi - xtandi is indicated for:the treatment of adult men with metastatic hormone-sensitive prostate cancer (mhspc) in combination with androgen deprivation therapy (see section 5. the treatment of adult men with high-risk non-metastatic castration-resistant prostate cancer (crpc) (see section 5. the treatment of adult men with metastatic crpc who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated (see section 5. the treatment of adult men with metastatic crpc whose disease has progressed on or after docetaxel therapy.